Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives $17.25 Consensus Price Target from Brokerages

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have been assigned an average rating of “Hold” from the six ratings firms that are covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $17.25.

Several brokerages have recently commented on AUPH. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $15.00 target price (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 5th. Bloom Burton lowered Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a report on Wednesday, November 5th. Leerink Partners lowered Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and boosted their price objective for the company from $15.00 to $16.00 in a research report on Wednesday, December 3rd. Jefferies Financial Group raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the company from $10.00 to $21.00 in a report on Friday, November 7th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, January 21st.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. BOK Financial Private Wealth Inc. acquired a new position in Aurinia Pharmaceuticals during the 4th quarter valued at about $32,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at $48,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at $82,000. State of Alaska Department of Revenue bought a new stake in Aurinia Pharmaceuticals in the third quarter worth about $91,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter valued at about $92,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Trading Up 0.6%

NASDAQ AUPH opened at $14.31 on Friday. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of 25.55 and a beta of 1.50. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.76 and a quick ratio of 5.17. Aurinia Pharmaceuticals has a 12 month low of $6.55 and a 12 month high of $16.54. The company’s fifty day moving average price is $15.20 and its two-hundred day moving average price is $13.77.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.